Journal of blood medicine · 2026
Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Xiaotong, Sun Yuting, Chen Yanyan, Dhurel Raj Singh, Zhang Chen, Xie Yutong, Ni Man, Chen Wei, Zhang Huanxin, Wu Qingyun, Li Depeng, Pan Bin, Yan Zhiling
Аннотация
PURPOSE: This study aimed to evaluate whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved long-term survival of patients with CD56-positive acute myeloid leukemia (AML).
PATIENTS AND METHODS: According to predefined inclusion and exclusion criteria, 188 patients with non-M3 AML, newly diagnosed between March 1, 2017, and May 1, 2024, were enrolled in this retrospective analysis. Patients were categorized according to CD56-expression status, ELN 2022 risk stratification, and treatment choices. Clinical characteristics, remission rates, disease-free survival (DFS), overall survival (OS), and cumulative incidence of relapse (CIR) were compared between patients with CD56-positive and CD56-negative diseases. Prognostic factors were analyzed, and the prognostic impact of CD56-expression was further evaluated within transplanted and non-transplanted subgroups.
RESULTS: The median follow-up time was 1102 days (interquartile range, 632-1942 days). In the CD56-positive subgroup, patients with non-transplanted had lower 3-year OS than those with allo-HSCT (22.8% vs 73.1%; P< 0.001). In the ELN 2022 adverse-risk subgroup, patients with CD56-positive disease had lower 1-year OS than those with CD56-negative disease (42.9% vs 65.3%; P = 0.035). Among the non-transplanted subgroups, patients with CD56-positive disease had similar 1-year cumulative survival (58.6% vs 64.1%, P = 0.583), but lower 3-year cumulative survival as compared with those who with CD56-negative disease (22.8% vs 32.0%, P = 0.031). Among the patients receiving allotransplants, no differences were observed in 1-year cumulative survival or 3-year cumulative survival between CD56-positive and CD56-negative patients (P = 0.969 vs P = 0.968). Multivariate analysis identified allo-HSCT (HR = 0.14, P < 0.01) and risk stratification as independent prognostic factors for CD56-positive patients.
CONCLUSION: Allo-HSCT might improve long-term survival in patients with CD56-positive AML.
PATIENTS AND METHODS: According to predefined inclusion and exclusion criteria, 188 patients with non-M3 AML, newly diagnosed between March 1, 2017, and May 1, 2024, were enrolled in this retrospective analysis. Patients were categorized according to CD56-expression status, ELN 2022 risk stratification, and treatment choices. Clinical characteristics, remission rates, disease-free survival (DFS), overall survival (OS), and cumulative incidence of relapse (CIR) were compared between patients with CD56-positive and CD56-negative diseases. Prognostic factors were analyzed, and the prognostic impact of CD56-expression was further evaluated within transplanted and non-transplanted subgroups.
RESULTS: The median follow-up time was 1102 days (interquartile range, 632-1942 days). In the CD56-positive subgroup, patients with non-transplanted had lower 3-year OS than those with allo-HSCT (22.8% vs 73.1%; P< 0.001). In the ELN 2022 adverse-risk subgroup, patients with CD56-positive disease had lower 1-year OS than those with CD56-negative disease (42.9% vs 65.3%; P = 0.035). Among the non-transplanted subgroups, patients with CD56-positive disease had similar 1-year cumulative survival (58.6% vs 64.1%, P = 0.583), but lower 3-year cumulative survival as compared with those who with CD56-negative disease (22.8% vs 32.0%, P = 0.031). Among the patients receiving allotransplants, no differences were observed in 1-year cumulative survival or 3-year cumulative survival between CD56-positive and CD56-negative patients (P = 0.969 vs P = 0.968). Multivariate analysis identified allo-HSCT (HR = 0.14, P < 0.01) and risk stratification as independent prognostic factors for CD56-positive patients.
CONCLUSION: Allo-HSCT might improve long-term survival in patients with CD56-positive AML.